By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Latest World News UpdateLatest World News UpdateLatest World News Update
  • Home
  • Business
  • National
  • Entertainment
  • Sports
  • Lifestyle
  • Health
  • Science
  • Tech
  • World
  • Marathi
  • Gujarati
  • Hindi
  • Press Release
    • Press Release Distribution Packages
Notification Show More
Font ResizerAa
Latest World News UpdateLatest World News Update
Font ResizerAa
  • Home
  • Business
  • National
  • Entertainment
  • Sports
  • Lifestyle
  • Health
  • Science
  • Tech
  • World
  • Marathi
  • Gujarati
  • Hindi
  • Press Release
    • Press Release Distribution Packages
Follow US
Latest World News Update > Blog > Business > Meril Presents Successful LANDMARK RCT One-Year Results at Prestigious EuroPCR 2025 – World News Network
Business

Meril Presents Successful LANDMARK RCT One-Year Results at Prestigious EuroPCR 2025 – World News Network

worldnewsnetwork
Last updated: May 22, 2025 12:00 am
By worldnewsnetwork
Share
6 Min Read
SHARE

PRNewswire
Vapi (Gujarat) [India], May 22: Meril Life Sciences announced one-year results from its pivotal LANDMARK trial, presented during the prestigious Late-Breaking Trial session at EuroPCR 2025, one of the world’s premier cardiology conferences held annually in Paris, France. The LANDMARK trial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis.
The Myval THV series demonstrated non-inferiority to contemporary THVs in terms of 1-year clinical efficacy composite endpoint (Myval THV Series: 13% vs. Contemporary THV: 13.1%, difference: -0.1%, one-sided 95% CI: 3.9%, Pnoninferiority < 0.0001).
Additionally, in the composite endpoint of clinical efficacy combined with QoL, outcomes were comparable (Myval THV Series: 19.5% vs. Contemporary THVs: 22.7%, difference: -3.2%, 95% CI: -9.2 to 2.9, P=0.33). Hemodynamic parameters including effective orifice area (EOA), mean pressure gradient (PG), and incidence of moderate or greater aortic regurgitation remained stable and similar across all treatment arms.
Survival rates were nearly identical (Myval THV Series: 92.8% vs. Contemporary THVs: 92.9%), and QoL improvements were comparable, reinforcing the overall safety and durability of the Myval THV series in everyday clinical use.
Professor Patri c k Serruys, Chairman and Study Director of the LANDMARK trial, said: “This trial reflects a new era in comparative valve research. The meticulous design and adherence to VARC-3 standards, including QoL endpoints, mark it as a pivotal study. The results of the LANDMARK trial represent a meaningful advancement for the global structural heart community–and most importantly, for patients receiving TAVI. The data not only validate the safety and efficacy of the Myval THV series, but also spotlight its adaptability to complex anatomies. This versatility is exactly what clinicians need to deliver precision care across a broad spectrum of patients.”
Professor Andreas Baumbach, Global Principal Investigat or, said: “The LANDMARK trial represents a significant step forward in TAVI research. For the first time, we’ve benchmarked Myval against both balloon-expandable and self-expanding platforms in a rigorous randomized setting. The one-year results demonstrates that the new generation Myval THV series can match global standards in safety and efficacy.”
Mr. Sanjeev Bhatt, Senior Vice President – Corporate Strategy at Meril, said: “The LANDMARK trial represents a significant milestone not just for Meril, but for the global TAVI community. The strong one-year results affirm the Myval THV series as a next-generation solution that delivers consistent safety, clinical efficacy, and improved quality of life across geographies. As the only head-to-head trial of its kind to include both balloon-expandable and self-expanding valves, it reinforces Myval THV series’s versatility and real-world relevance for diverse patient anatomies and healthcare systems. At Meril, we are proud to contribute innovative, evidence-based technologies that are reshaping patient care and expanding access to advanced structural heart therapies worldwide.”
The trial is designed to follow patients for a period of 10 years, aiming to generate long-term insights into clinical and echocardiographic outcomes, with a focus on valve durability and sustained performance.

About THE LANDMARK TRIAL:
The LANDMARK trial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis. The LANDMARK trial was a prospective, randomized, multicenter, open-label, non-inferiority trial involving 768 patients who underwent Transcatheter Aortic Valve Implantation (TAVI) for the treatment of aortic stenosis. The first patient was enrolled in the LANDMARK trial on 6 January 2021 and the last patient was enrolled on 5 December 2023. The trial included a total of 768 patients at 31 sites across 16 countries (Brazil, New Zealand, and some countries of Europe). The 30-day primary composite endpoints highlighting the safety and efficacy outcomes of the LANDMARK trial have been successfully published in The Lancet and EuroIntervention, two of the most prestigious peer-reviewed medical journals.
About Meril Life Sciences:
Meril is a global medical device company based in India, committed to advancing healthcare through innovation. With a strong focus on research and development, Meril delivers cutting-edge medtech solutions across more than 135 countries and has a robust presence through subsidiaries in the USA, Brazil, Europe, Asia, Africa, and Australia. Through partnerships, precision technology, and adherence to international quality standards, Meril is helping reshape the future of healthcare.
Media Contact: media@merillife.com
Photo: https://mma.prnewswire.com/media/2694081/Meril_Myval_THV_series.jpg
Logo: https://mma.prnewswire.com/media/2694080/Meril_and_LANDMARK_Logo.jpg
(ADVERTORIAL DISCLAIMER: The above press release has been provided by PRNewswire. ANI will not be responsible in any way for the content of the same)

Contents
WORLD MEDIA NETWORKPRESS RELEASE DISTRIBUTIONPress releases distribution in 166 countriesPress releases in all languagesPress releases in Indian LanguagesIndia PackagesEurope PackagesAsia PackagesMiddle East & Africa PackagesSouth America PackagesUSA & Canada PackagesOceania PackagesCis Countries PackagesWorld Packages

Disclaimer: This story is auto-generated from a syndicated feed of ANI; only the image & headline may have been reworked by News Services Division of World News Network Inc Ltd and Palghar News and Pune News and World News

sponsored by

WORLD MEDIA NETWORK


PRESS RELEASE DISTRIBUTION

Press releases distribution in 166 countries

EUROPE UK, INDIA, MIDDLE EAST, AFRICA, FRANCE, NETHERLANDS, BELGIUM, ITALY, SPAIN, GERMANY, AUSTRIA, SWITZERLAND, SOUTHEAST ASIA, JAPAN, SOUTH KOREA, GREATER CHINA, VIETNAM, THAILAND, INDONESIA, MALAYSIA, SOUTH AMERICA, RUSSIA, CIS COUNTRIES, AUSTRALIA, NEW ZEALAND AND MORE

Press releases in all languages

ENGLISH, GERMAN, DUTCH, FRENCH, PORTUGUESE, ARABIC, JAPANESE, and KOREAN CHINESE, VIETNAMESE, INDONESIAN, THAI, MALAY, RUSSIAN. ITALIAN, SPANISH AND AFRICAN LANGUAGES

Press releases in Indian Languages

HINDI, MARATHI, GUJARATI, TAMIL, TELUGU, BENGALI, KANNADA, ORIYA, PUNJABI, URDU, MALAYALAM
For more details and packages

Email - support@worldmedianetwork.uk
Website - worldmedianetwork.uk

India Packages

Read More

Europe Packages

Read More

Asia Packages

Read More

Middle East & Africa Packages

Read More

South America Packages

Read More

USA & Canada Packages

Read More

Oceania Packages

Read More

Cis Countries Packages

Read More

World Packages

Read More
sponsored by
Share This Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Fast Four Quiz: Precision Medicine in Cancer

How much do you know about precision medicine in cancer? Test your knowledge with this quick quiz.
Get Started
APSEZ breaks records: Handles 420 MMT cargo globally, sets new milestones in March 2024 – World News Network

The company announced that it achieved its highest ever monthly cargo volumes,…

Stock market opens on a bullish note: Nifty-Sensex surge – World News Network

Simultaneously, the BSE Sensex followed suit, leaping by 317.27 points or 0.43…

IIHM Institute of Hospitality Skills (IIHS) opens largest training centre in Udaipur – World News Network

New Delhi [India], April 1: IIHM Institute of Hospitality Skills (IIHS), India's…

Your one-stop resource for medical news and education.

Your one-stop resource for medical news and education.
Sign Up for Free

You Might Also Like

Audi India unveils Audi Drive Sure for responsible driver education – World News Network

By worldnewsnetwork

KRAFTON India Strengthens Investment Portfolio by Backing Hyperlocal Community App Leader Shuru – World News Network

By worldnewsnetwork

One third of India’s Gen Z participating in securities market: SEBI Chief – World News Network

By worldnewsnetwork

Dilesh Sahu, Anikriti Chowhan & Kaushal Upadhyay Bring Chhattisgarh to the National Stage with ‘Janki’ – World News Network

By worldnewsnetwork

Sports

Tottenham edge past Manchester United to win Europa League, ending 17-year wait for a trophy – World News Network
Sports
Playing to resonant tune crucial for Indian football team, emphasises AIFF Player of the Year Subhasish Bose – World News Network
Sports

Popular Category

  • Business
  • Entertainment
  • Health
  • Lifestyle
  • National
  • Science
  • Sports
  • Tech
  • Videos
  • World
  • Marathi
  • Hindi
  • Gujarati
  • Press Release
  • Press Release Distribution Packages

Entertainment

Zach Braff to join medical sitcom ‘Scrubs’ reboot – World News Network
Entertainment
Tom Cruise addresses viral video of him eating popcorn at movie screening – World News Network
Entertainment
Latest World News UpdateLatest World News Update
Copyright © 2024 World News Network. All Rights Reserved
Welcome Back!

Sign in to your account

Lost your password?